IL131995A0 - Gastric-retained pharmaceutical compositions - Google Patents

Gastric-retained pharmaceutical compositions

Info

Publication number
IL131995A0
IL131995A0 IL13199598A IL13199598A IL131995A0 IL 131995 A0 IL131995 A0 IL 131995A0 IL 13199598 A IL13199598 A IL 13199598A IL 13199598 A IL13199598 A IL 13199598A IL 131995 A0 IL131995 A0 IL 131995A0
Authority
IL
Israel
Prior art keywords
gastric
pharmaceutical compositions
retained
retained pharmaceutical
compositions
Prior art date
Application number
IL13199598A
Other languages
English (en)
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of IL131995A0 publication Critical patent/IL131995A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
IL13199598A 1997-04-18 1998-04-15 Gastric-retained pharmaceutical compositions IL131995A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9704803A FR2762213B1 (fr) 1997-04-18 1997-04-18 Composition pharmaceutique a retention gastrique
PCT/FR1998/000755 WO1998047506A1 (fr) 1997-04-18 1998-04-15 Composition pharmaceutique a residence gastrique

Publications (1)

Publication Number Publication Date
IL131995A0 true IL131995A0 (en) 2001-03-19

Family

ID=9506077

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13199598A IL131995A0 (en) 1997-04-18 1998-04-15 Gastric-retained pharmaceutical compositions

Country Status (19)

Country Link
EP (1) EP0983065A1 (ar)
JP (1) JP2001523241A (ar)
KR (1) KR20010006353A (ar)
CN (1) CN1252720A (ar)
AR (1) AR015586A1 (ar)
AU (1) AU737634B2 (ar)
CA (1) CA2286081A1 (ar)
FR (1) FR2762213B1 (ar)
HU (1) HUP0002455A3 (ar)
IL (1) IL131995A0 (ar)
JO (1) JO2017B1 (ar)
MA (1) MA26482A1 (ar)
NO (1) NO995039L (ar)
NZ (1) NZ500288A (ar)
PE (1) PE68199A1 (ar)
PL (1) PL336273A1 (ar)
TN (1) TNSN98049A1 (ar)
WO (1) WO1998047506A1 (ar)
ZA (1) ZA983258B (ar)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
FR2784583B1 (fr) * 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
FR2790388B1 (fr) * 1999-03-04 2001-04-13 Synthelabo Compositions pharmaceutiques comprenant un benzamide et au moins un promoteur d'absorption
EP1245227A1 (en) 2001-03-31 2002-10-02 Jagotec Ag A pharmaceutical tablet system that floats in the stomach for programmed release of active substance and process of producing buoyant material contained in same
FR2949061B1 (fr) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
DK2719376T3 (en) 2012-10-12 2015-06-15 Omya Int Ag Gastroretentiv drug formulation and delivery systems and their method of preparation by the use of functional calcium carbonate
WO2019113084A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
CN118593482A (zh) 2017-12-05 2024-09-06 赛诺维信制药公司 非外消旋混合物及其用途
JP7044649B2 (ja) * 2018-06-28 2022-03-30 株式会社ファンケル 胃内浮遊錠剤
MX2021014774A (es) 2019-06-04 2022-02-03 Sunovion Pharmaceuticals Inc Formulaciones de liberacion modificada y usos de las mismas.
US20220323409A1 (en) * 2019-06-04 2022-10-13 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
WO2023214018A1 (en) 2022-05-06 2023-11-09 Galenix Innovations Gastro-retentive swellable sustained release composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
FR2554718B1 (fr) * 1983-11-14 1986-04-04 Ethypharm Sa Nouvelles formes galeniques du sulpiride utilisables par voie orale
FR2556964A1 (fr) * 1983-12-23 1985-06-28 Ile De France Nouvelles formes galeniques du sulpiride utilisables par voie orale
JPS62178518A (ja) * 1986-01-30 1987-08-05 Toho Yakuhin Kogyo Kk 新規持続性スルピリド錠剤
JPH0776172B2 (ja) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 マトリツクス錠
CA2039742A1 (en) * 1990-04-23 1991-10-24 Andrew B. Dennis Tablet composition and method for problem pharmaceutical materials

Also Published As

Publication number Publication date
NO995039L (no) 1999-12-17
NO995039D0 (no) 1999-10-15
JO2017B1 (ar) 1999-05-15
NZ500288A (en) 2001-03-30
EP0983065A1 (fr) 2000-03-08
AU737634B2 (en) 2001-08-23
CN1252720A (zh) 2000-05-10
WO1998047506A1 (fr) 1998-10-29
PL336273A1 (en) 2000-06-19
FR2762213B1 (fr) 1999-05-14
MA26482A1 (fr) 2004-12-20
AR015586A1 (es) 2001-05-16
TNSN98049A1 (fr) 2005-03-15
AU7341698A (en) 1998-11-13
ZA983258B (en) 1998-10-19
HUP0002455A3 (en) 2001-01-29
HUP0002455A2 (hu) 2000-12-28
JP2001523241A (ja) 2001-11-20
PE68199A1 (es) 1999-07-15
KR20010006353A (ko) 2001-01-26
CA2286081A1 (en) 1998-10-29
FR2762213A1 (fr) 1998-10-23

Similar Documents

Publication Publication Date Title
GB9727053D0 (en) Pharmaceutical compositions
EG24118A (en) Pharmaceutical compositions
GB9706089D0 (en) Pharmaceutical composition
GB9616672D0 (en) Pharmaceutical compositions
GB9610359D0 (en) Pharmaceutical compositions
GB9717444D0 (en) Pharmaceutical composition
HRP980154B1 (en) Pharmaceutical compositions
HUP0002455A3 (en) Gastric-retained pharmaceutical composition
GB9723985D0 (en) Pharmaceutical compositions
GB9717428D0 (en) Pharmaceutical composition
GB9622681D0 (en) Pharmaceutical compositions
HUP0004669A3 (en) Pharmaceutical compositions
GB9606429D0 (en) Pharmaceutical compositions
HU9700632D0 (en) Pharmaceutical compositions
GB9613457D0 (en) Pharmaceutical compositions
GB9717770D0 (en) Pharmaceutical composition
GB9618376D0 (en) Pharmaceutical compositions
GB9610136D0 (en) Pharmaceutical compositions
GB2295825B (en) Pharmaceutical compositions
GB9921495D0 (en) Pharmaceutical compositions
GB2321190B (en) Pharmaceutical composition
GB9726781D0 (en) Pharmaceutical composition
GB9718270D0 (en) Pharmaceutical compositions
GB9825499D0 (en) Pharmaceutical compositions
GB9722066D0 (en) Pharmaceutical compositions